Publications by authors named "Nathan Morgan"

Claim this Profile
A
Accurately Predicting Solubility Curves via a Thermodynamic Cycle, Machine Learning, and Solvent Ensembles.
Emad Al Ibrahim, Nathan Morgan, Simon Müller, Saikiran Motati, William H Green

J Am Chem Soc· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescription drug pricing on a Bitcoin standard: Rethinking health care affordability amid fiat inflation.
James Wong, Amar Lunagaria, Nathan Morgan, Elaine J Law

J Am Pharm Assoc (2003)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASKCOS: Open-Source, Data-Driven Synthesis Planning.
Zhengkai Tu, Sourabh J Choure, Mun Hong Fong, Jihye Roh, Itai Levin, Nathan Morgan

Acc Chem Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring Cuneanes as Potential Benzene Isosteres and Energetic Materials: Scope and Mechanistic Investigations into Regioselective Rearrangements from Cubanes.
Jeong-Yu Son, Santeri Aikonen, Nathan Morgan, Alexander S Harmata, Jesse J Sabatini

J Am Chem Soc· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-Quasi-Favorskii Reaction: Construction of Highly Substituted Aziridines through a Concerted Multibond Rearrangement Process.
Padmanabha V Kattamuri, Jidong Zhao, Tamal Kanti Das, Juha H Siitonen, Nathan Morgan

J Am Chem Soc· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).
Jun Li, Lawrence J Kennedy, Steven J Walker, Haixia Wang, James J Li, Nathan N Morgan

ACS Med Chem Lett· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
Xiang-Yang Ye, Stephanie Y Chen, Shung Wu, David S Yoon, Haixia Wang, Nathan N Morgan

J Med Chem· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists.
Hao Zhang, Charles Z Ding, Zhi Lai, Sean S Chen, Pratik Devasthale, Nathan Morgan

Bioorg Med Chem Lett· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).
Jun Li, Lawrence J Kennedy, Haixia Wang, James J Li, Steven J Walker, Nathan N Morgan

ACS Med Chem Lett· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).
Pratik Devasthale, Ying Wang, Wei Wang, John Fevig, JianXin Feng, Nathan Morgan

J Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1).
Shung C Wu, David Yoon, Janice Chin, Katy van Kirk, Ramakrishna Seethala, Nathan N Morgan

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
7
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.
Wei Wang, Pratik Devasthale, Aiying Wang, Tom Harrity, Don Egan, Nathan Morgan

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.
Hao Zhang, Denis E Ryono, Pratik Devasthale, Wei Wang, Kevin O'Malley, Nathan Morgan

Bioorg Med Chem Lett· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
Bruce A Ellsworth, Wei Meng, Manorama Patel, Ravindar N Girotra, Gang Wu, Nathan N Morgan

Bioorg Med Chem Lett· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Wei Meng, Bruce A Ellsworth, Alexandra A Nirschl, Peggy J McCann, Manorama Patel, Nathan Morgan

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.
Wei Wang, Pratik Devasthale, Dennis Farrelly, Liqun Gu, Thomas Harrity, Nathan Morgan

Bioorg Med Chem Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis